JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis

Leukemia. 2014 Aug;28(8):1736-8. doi: 10.1038/leu.2014.86. Epub 2014 Feb 26.

Authors

T Stübig¹, H Alchalby¹, M Ditschkowski², D Wolf³, G Wulf⁴, T Zabelina¹, C Wolschke¹, F Ayuk¹, N Kröger¹

Affiliations

¹ Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
² Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany.
³ Medical Clinic III, Oncology, Hematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany.
⁴ Department of Hematology/Oncology, University Hospital Göttingen, Göttingen, Germany.

PMID: 24569777
DOI: 10.1038/leu.2014.86

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Female
Hematopoietic Stem Cell Transplantation*
Humans
Janus Kinases / antagonists & inhibitors*
Male
Middle Aged
Nitriles
Primary Myelofibrosis / drug therapy*
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Pyrimidines
Transplantation, Homologous

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib
Janus Kinases